Background: Insulin resistance (IR) is one of the important causes of abnormal glucose homeostasis in CKD even in the absence of overt diabetes mellitus. Retinol-binding protein 4 (RBP4) is a lipocalin superfamily molecule that is synthesized primarily by hepatocytes and adipocytes. CKD may contribute to the increased survival and retention of RBP4 in the circulation. RBP has recently been proposed as a novel adipokine involved in the metabolism of glucose. Objective:
Introduction:
Insulin resistance is defined as reduced sensitivity of target organs to the biologic effects of insulin. Insulin resistance is often distinguished as either hepatic insulin resistance or peripheral insulin resistance. Hepatic insulin resistance refers to impaired suppression of hepatic glucose production, whereas peripheral insulin resistance refers to impaired response to insulin in skeletal muscle and adipose tissue.
(1)
The site of insulin resistance in CKD is localized to skeletal muscles.
(2)
Insulin resistance is increasingly recognized as a 'nontraditional' risk factor contributing to cardiovascular disease through endothelial dysfunction, oxidative stress, dyslipidemia, systemic inflammation, and activation of the reninangiotensin-aldosterone system.
(3)
Insulin resistance is common in end-stage renal disease (ESRD), and possibly also in moderate-to severe stages of CKD. Therefore, insulin resistance may be an important therapeutic target for reduction of cardiovascular mortality in patients with CKD. Insulin resistance in dialysis patients has been linked to accelerated protein catabolism leading to protein energy wasting and malnutrition.
(4)
Numerous factors related to CKD have been implicated in the etiology of insulin resistance.
(5)
These include uremic toxins (enhanced protein carbamylation), chronic metabolic acidosis, intracellular ion homeostasis disequilibrium, as well as qualitative and quantitative disturbances of insulin receptors on adipocytes, skeletal muscle cells and hepatocytes, cytokines produced by adipocytes (adipocytokines), chronic inflammation as well as low physical activity. (5) Initiation of renal replacement therapy by dialysis in patients with irreversible kidney failure has long been suggested to have a positive effect on the reduction of insulin resistance in this group of patients. Adipose tissue-derived circulating hormones, or adipokines, may offer new opportunity to assess insulin resistance in CKD.
(7) Retinol-binding protein 4 (RBP4) is a 21 kDa non-glycosylated, nonphosphorylated, and non-sulfated molecule.
(8)
It is a lipocalin superfamily molecule that is synthesized primarily by hepatocytes and adipocytes.
(9) This liverderived transport protein retinol-binding protein (RBP) has recently been proposed as a novel adipokine involved in the metabolism of glucose.
(10)
Elevated plasma levels of the insulin resistance-associated adipokines RBP4 and resistin was reported in CKD patients (11 
Exclusion:
We exclude diabetic patients, Obese individuals with BMI > 30,patients with chronic liver disease (HCV +ve, HBV +ve and liver cirrhosis by U/S), in efficient dialysis detected by urea reduction ratio < 60 and children less than 18 years old. All individuals were subjected to the following after taking an informed consent. 1.
Full history specially including hemodialysis data.
2.
Clinical examination with special emphasis on (BMI). A monoclonal antibody specific for RBP4 has been pre coated onto a microplate. Standards and samples are pipetted into the wells and any RBP4 present is bound by the immobilized antibody. After washing away any unbound substances, an enzyme linked monoclonal antibody specific for RBP4 is added to the wells. Following a wash to remove any unbound antibody enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of RBP4 bound in the initial step. The color development is stopped and the intensity of the color is measured. Method of assessment of insulin level (reference range: 2 µIU/mL to 25 µIU/mL) Enzyme immune assay for insulin store at 2-8C: The insulin ELISA is an enzyme immunoassay for the quantitative in vitro diagnostic measurement of insulin in serum and plasma.
Principle of the test:
The insulin ELISA kit is a solid phase enzyme linked immunosorbent assay (ELISA) based on the sandwich principle. The microtitre wells are coated with a monoclonal antibody directed towards a unique antigenic site on the insulin molecule. An aliquot of patient sample containing endogenous insulin is incubated in the coated well with enzyme conjugate, which is an anti-insulin antibody conjugated with biotin. After incubation the unbound conjugate is washed off. During the second incubation step streptavidin peroxidase enzyme complex binds to the biotin anti insulin antibody. The amount of bound HRP complex is proportional to the concentration of insulin in the sample. Having added the substrate solution, the intensity of colour developed is proportional to the concentration of insulin in the patient sample.
Results:
This study was conducted on 100 individuals divided into two groups of comparable age and sex as follows: The relative amounts of apo-RBP4 are increased during acute renal failure and RBP4-L and RBP4-LL have been shown to be increased in hemodialysis patients.
(13)
RBP4 was shown to induce expression of the gluconeogenic enzyme phosphoenol pyruvate carboxy kinase and decrease insulin signaling in muscle. (14) There are multiple mechanisms described by which RBP4 can affect changes in glucose metabolism.
Retinol-dependent mechanisms may use different retinol isomers to affect insulin sensitivity and insensitivity,
whereas retinolindependent mechanisms may affect metabolism through cell surface receptors. (14) The cell surface protein megalin (gp320) is the only RBP4 receptor known so far, but the reported binding affinity is low. However, RBP4 binds to a wide range of retinoids and is likely to transport other lipophilic molecules that may mediate its effect on glucose.
(16)
This case control study included one hundred subjects above 18 years old to study the relation of retinol binding protein 4 and insulin resistance in hemodialysis patients in Ain Shams University hospitals. These subjects were divided into 2 groups:Group I:50 ESRD patients on regular hemodialysis 20 females (40.0%) and 30 males (60.0%) with mean age ±SD (38.08±7.1 years). Group II: 50 healthy individuals as a Control group 26 females (52%) and 24 males (48%) with mean age ±SD (35.38±8.77 years). According to insulin resistance (HOMA level) each group will be subdivided into two subgroups:
➢ Subgroup (A) when HOMA<2. ➢ Subgroup (B) when HOMA >2. In this study there was highly significant increase in RBP4 in hemodialysis patients compared with the control group which agreed with Ziegelmeier et al. (17) who studied RBP4 in diabetic and non diabetic ESRD on regular hemodialysis and compared its level in normal controls and found significant increase in RBP4 in HD patients than in healthy controls and Frey et al.
(18) who studied serum levels of RBP4, apo-RBP4, holo-RBP4, RBP4-L, RBP4-LL, retinol and transthyretin in hemodialysis patients and in healthy controls and found that HD patients had elevated levels of RBP4 than in normal controls. In this study we found highly statistically significant increase in FBG in hemodialysis patients compared with the control group which agreed with Becker et al. (19) who studied insulin resistance in chronic kidney disease patients not on hemodialysis and compared it with normal population and found significant increase in fasting blood glucose in CKD patients than in normal.
Also we found significant increase in fasting blood insulin in hemodialysis patients in comparison to controls which agreed with Becker et al. (19) who studied insulin resistance in chronic kidney disease patients not starting hemodialysis and compared it with normal population and found significant increase in fasting blood insulin in comparison to control group but our results were not compatible with Ziegelmeier et al. (17) who studied insulin resistance in HD patients and compared it with normal healthy controls and found that fasting blood insulin was not increased in HD patients than in controls. There was no statistically significant difference between the two studied groups regarding 2h post challenge blood glucose which is in contrast with Fliser et al. (20) who examined patients with IgA glomerulonephritis (IgAGN) and patients with adult polycystic kidney disease (ADPKD) in different stages of renal failure, and in addition, healthy agematched subjects. Insulin sensitivity and other variables of glucose metabolism were assessed using a frequent sampling intravenous glucose tolerance test and found statistically significant difference between the studied groups regarding 2h post challenge blood glucose and document that insulin resistance and concomitant hyperinsulinemia present early in the course of renal disease, that is, even in patients with GFR within the normal range, irrespective of the type of renal disease. Despite significant increase in FBI and FBG in hemodialysis patients than in controls there was no statistically significant difference in insulin resistance (HOMA level) between the two studied groups which agrees with Kobayashi et al (6) who studied non diabetic ESRD as regard insulin resistance before and after start of hemodialysis and compared the results with normal population and found that mean duration of hemodialysis therapy of 4-9 weeks completely normalize insulin sensitivity also our results were compatible with Defronzo et al. (21) who studied also non diabetic ESRD as regard insulin resistance before and after start of hemodialysis and compared the results with normal population and demonstrated that 10 weeks of hemodialysis therapy resulted in a marked improvement in glucose metabolism but not completely normalize glucose utilization. And this may explain the absence of difference in HOMA level between HD patients and controls as mean duration of hemodialysis therapy in our patients were 8 years also this may be explained by HOMA primarily reflects hepatic IR rather than peripheral IR (22) and estimates of IR based on fasting insulin concentration may not be adequate in patients with CKD as it largely reflects hepatic defects, whereas CKD impairs insulin catabolism .
(23)
. Mak et al. (24) . also studied insulin resistance in hemodialysis patients and compared it to normal population and demonstrated that insulin resistance improved markedly after treatment with 1,25 dihydroxycholecalciferol and this was compatible with our results as all our patients were on 1,25 dihydroxycholecalciferol with acceptable Ca and P.
Comparison between subgroups Ia&Ib in our results as regard FBI show highly significant increase when HOMA >2 and as regard 2hPP showed significant increase when HOMA >2. Comparison between subgroups IIa&IIb as regard FBI&2hPP show highly significant increase when HOMA >2 and significant increase in serum albumin when HOMA> 2. In this study we found no correlation between RBP4 and HOMA, BMI, FBI and FBG in hemodialysis patients which is agreed with Ziegelmeier et al. (17) , who studied RBP4 in HD patients and compared it in normal healthy controls and its relation to insulin resistance in both groups and found that no correlation between RBP4 and HOMA, BMI, FBI and FBG. We found highly significant positive correlation between HOMA, FBI and glucose tolerance (2 hs post challenge blood glucose) and significant positive correlation between HOMA and FBG in hemodialysis patients and in controls which agrees with Qu H-Q et al. (25) who studied insulin resistance in normal healthy individuals and found positive correlation between HOMA, FBI and glucose tolerance (2 hs post challenge blood glucose) and significant positive correlation between HOMA and FBG. As regard the Comparison of laboratory results between hemodialysis patients and control group there was statistically significant increase in Na in control group (P 0.031) and also a highly significant difference was found regarding Hb, Ca and Alb which showed a decrease in group I (P 0.000), while P, PTH and K were increased in patient group (P 0.000).
The comparison between HOMA levels in the subgroups Ia & Ib showed a highly statistically significant increase in FBI (P 0.000) and 2h post challenge blood glucose (P 0.012) in subgroup Ib (HOMA level > 2),but there was no statistically significant difference regarding RBP4. Comparison between subgroup IIA and subgroup II B regarding glucoparameters and RBP4 showed a highly significant increase in FBI and 2h post challenge blood glucose (P 0.000) when HOMA level > 2, but there was no statistically significant difference regarding RBP4 according to HOMA level. The correlation between HOMA and RBP4 and the studied parameters in the hemodialysis patients showed statistically significant positive correlation between HOMA and BMI (P 0.31) and FBG (P 0.028), and also showed a highly significant positive correlation with FBI (P 0.000) and 2 hours post challenge blood glucose (P 0.000). While the RBP4 showed no significant relation with any of the studied parameters.
Conclusion:
Elevated levels of RBP4 in hemodialysis patients than in controls with cut off point > 26000 ng/ml with sensitivity 93.18%, specificity 100.00%.than in controls also we found significant increase in FBG and FBI in HD patients than in controls but no difference between the two studied groups as regard insulin resistance measured by HOMA. HOMA was positively correlated with FBI, 2hPP and BMI in both HD patients and in controls. No correlation between RBP4 and HOMA, BMI, FBI and FBG in hemodialysis patients. 
